AnaptysBio, Inc. (ANAB) News
Filter ANAB News Items
ANAB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ANAB News Highlights
- For ANAB, its 30 day story count is now at 4.
- Over the past 27 days, the trend for ANAB's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about ANAB are BDSI and BEAT.
Latest ANAB News From Around the Web
Below are the latest news stories about Anaptysbio Inc that investors may wish to consider to help them evaluate ANAB as an investment opportunity.
AnaptysBio, Inc. (ANAB) Earnings Expected to Grow: What to Know Ahead of Q4 ReleaseAnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Amgen''s (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer | Investing.comStocks Analysis by Zacks Investment Research covering: Amgen Inc, Dynavax Technologies Corporation, Mirati Ther, AnaptysBio Inc. Read Zacks Investment Research''s latest article on Investing.com |
BioDelivery (BDSI) Stock Up on Raised Guidance for 2021BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance. |
Editas (EDIT) Focuses on Developing Gene-Editing Eye DrugEditas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe. |
AnaptysBio, Inc. (ANAB): Hedge Funds Are Snapping UpHedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don''t make them change their opinion towards a |
AnaptysBio, Inc.'s (NASDAQ:ANAB) Intrinsic Value Is Potentially 23% Below Its Share PriceHow far off is AnaptysBio, Inc. ( NASDAQ:ANAB ) from its intrinsic value? Using the most recent financial data, we'll... |
Recludix Pharma Announces Scientific Advisory BoardSAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the establishment of its scientific advisory board. “We are thrilled to have established a group of distinguished scientific thought leaders as advisors to the company,” said Nancy Whiting, Pharm.D., chief executive officer of Recludix. “Our scientific advisory board consists of pioneers in precision medicine |
AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare ConferenceSAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio as part of the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 from 8:15 8:55 a.m. ET. |
Anaptysbio Inc (ANAB) President, CEO Hamza Suria Sold $1.3 million of SharesPresident, CEO of Anaptysbio Inc (30-Year Financial, Insider Trades) Hamza Suria (insider trades) sold 36,645 shares of ANAB on 12/20/2021 at an average price of $35.57 a share. |
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Purchased by Invesco Ltd.Invesco Ltd. boosted its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 7.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,083 shares of the biotechnology company’s stock after acquiring an additional 1,330 shares during the period. Invesco Ltd. owned 0.07% of […] The post AnaptysBio, Inc. (NASDAQ:ANAB) Shares Purchased by Invesco Ltd. appeared first on ETF Daily News . |